Advances on the hematopoietic stem cell transplantation for the treatment of multiple myeloma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 500-503, 2012.
Article
de Zh
| WPRIM
| ID: wpr-471368
Bibliothèque responsable:
WPRO
ABSTRACT
Hematopoietic cell transplantation is frontline treatment of multiple myeloma (MM).Autologous hematopoietic stem cell transplantation (auto-HSCT) could improve remission rate,prolong survival time,the tandem auto-HSCT is able to make patients get further benefits for patients not achieving at least very good partial remission after the first auto-HSCT.Allologous hematopoietic stem cell transplantation (alloHSCT) is potentially able to cure multiple myeloma,but patients achieve less benefit because of high transplant-related mortality (TRM).The TRM is low after reduced-intensity conditioning allo-HSCT,but which exhibit no survival benefit.Moreover,patients achieve no survival benefit after tandem auto-HSCT and allologous reduced-intensity conditioning transplantation.This paper reviewes recent studies about HSCT in MM.
Texte intégral:
1
Indice:
WPRIM
langue:
Zh
Texte intégral:
Journal of Leukemia & Lymphoma
Année:
2012
Type:
Article